Sundaram Global Brand Fund opens for subscription
Sundaram Global Brand Fund opens for subscription

Sundaram Global Brand Fund opens for subscription

Shashikant Singh Article rating: 2.7

Sundaram Mutual has launched a fund of fund scheme that will invest as a feeder fund into the Sundaram Global Brand Fund. Read on to find how to use this fund. 

Zydus Cadila receives USFDA approval for two products
Zydus Cadila receives USFDA approval for two products

Zydus Cadila receives USFDA approval for two products

Geyatee Deshpande Article rating: 3.0

Zydus Cadila has received final approval from THE USFDA to markets lsosorbide Dinitrate Tablets USP (US RLD - Isordil Tablet), in the strengths of 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg, and also for Desonide Cream (US RLD - Desonide Cream), 0.05%.

Market ends the session in red, IT stocks decline
Market ends the session in red, IT stocks decline

Market ends the session in red, IT stocks decline

Amir Shaikh Article rating: 5.0

Indian equity benchmarks traded weakly throughout the day on Friday and ended the session on a pessimistic note, led by a decline in IT stocks.

Lupin launches connected Smart Device-Adhero in India
Lupin launches connected Smart Device-Adhero in India

Lupin launches connected Smart Device-Adhero in India

Geyatee Deshpande Article rating: 3.0

Lupin has launched 'Adhero', which is the first-of-its-kind, connected smart device in India to track usage pattern of metered dose inhaler (MDI) by patients. The pharma major also announced the rollout of Hydrocortisone Valerate Cream USP, 0.2%, which is for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Dr. Reddy's Laboratories announces the launch of Doxercalciferol Injection
Dr. Reddy's Laboratories announces the launch of Doxercalciferol Injection

Dr. Reddy's Laboratories announces the launch of Doxercalciferol Injection

Geyatee Deshpande Article rating: 3.5

Dr. Reddy's has launched Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, a therapeutic generic equivalent of Hectorol (doxercalciferol) Injection 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, which has been approved by the U.S. Food and Drug Administration (USFDA).

IPO Analysis: CSB Bank
IPO Analysis: CSB Bank

IPO Analysis: CSB Bank

Shashikant Singh Article rating: 3.5

CSB Bank, one of the oldest private sector banks in India, with a history of over 98 years, is entering the capital market with its initial public offering. Read on to find if you should subscribe to it.

Coal India to develop new coal mines
Coal India to develop new coal mines

Coal India to develop new coal mines

Amir Shaikh Article rating: 5.0

Coal India is planning to develop 55 new coal mines and expand 193 existing ones in the next five years. The company is also undertaking portal-based monitoring of ongoing projects to ensure its timely completion.


Alembic Pharma gets USFDA approval for 3 ANDAs
Alembic Pharma gets USFDA approval for 3 ANDAs

Alembic Pharma gets USFDA approval for 3 ANDAs

Apurva Joshi Article rating: 5.0

Alembic Pharmaceuticals Limited has received the US Food & Drug Administration (USFDA) approvals for 3 of its ANDAs. It has total of 107 ANDA approvals (95 final approvals and 12 tentative approvals) from the USFDA.

How your financial advisers are getting paid?
How your financial advisers are getting paid?

How your financial advisers are getting paid?

Henil Shah Article rating: 4.1

Whether you invest in mutual funds or in stocks, your financial advisers or brokers are paid for the services they provide. But, do you know in what ways you pay them? Let’s find out.

Ten stocks close to their 52-week low
Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Abhishek Kapoor Article rating: 3.8

The market opened lower on Friday November 22. The previous day witnessed the sensex going down by 76.47 points to close at 40,575.17, while Nifty was down 30.70 points to close at 11,968.40



RSS
First24702471247224732475247724782479Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR